(Q46162422)

20 December 2017

title

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design (English)

1 reference

20 December 2017

0 references

5

Steven M Haffner

1 reference

20 December 2017

John McMurray

3

object named as

John J V McMurray

1 reference

20 December 2017

author name string

Hans-Henrik Parving

1

1 reference

20 December 2017

Barry M Brenner

2

1 reference

20 December 2017

Dick de Zeeuw

4

1 reference

20 December 2017

Scott D Solomon

6

1 reference

20 December 2017

Nish Chaturvedi

7

1 reference

20 December 2017

Mathieu Ghadanfar

8

1 reference

20 December 2017

Nicole Weissbach

9

1 reference

20 December 2017

Zhihua Xiang

10

1 reference

20 December 2017

Juergen Armbrecht

11

1 reference

20 December 2017

Marc A Pfeffer

12

1 reference

20 December 2017

language of work or name

English

0 references

publication date

14 January 2009

1 reference

20 December 2017

Nephrology Dialysis Transplantation

published in

1 reference

20 December 2017

volume

24

1 reference

20 December 2017

page(s)

1663-1671

1 reference

20 December 2017

issue

5

1 reference

20 December 2017

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

The incidence and implications of aldosterone breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Renin, prorenin and the putative (pro)renin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

Patient-important outcomes in registered diabetes trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN721

21 January 2018

Identifiers

DOI

10.1093/NDT/GFN721

1 reference

20 December 2017

PubMed ID

19145003

1 reference

20 December 2017